Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 15;2012(8):CD009063.
doi: 10.1002/14651858.CD009063.pub2.

Pregabalin for chronic prostatitis

Omar M Aboumarzouk  1 , Richard L Nelson
Affiliations

Pregabalin for chronic prostatitis

Omar M Aboumarzouk et al. Cochrane Database Syst Rev. .

Abstract

Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a condition that is detrimental to the quality of life of men. Evidence suggests that it may have a neuropathic origin and therefore medications such as pregabalin might have a role in the controlling of symptoms.

Objectives: The primary objective was to compare pregabalin to other modalities of pain relief to alleviate men's symptoms of CP/CPPS.The secondary objective was to assess the safety and effectiveness of pregabalin to improve various individual symptoms consistent with CP/CPPS.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to May 2012), EMBASE (1980 to May 2012), CINAHL, clinicaltrials.gov, Google Scholar, and reference lists of articles and abstracts from conference proceedings, without language restriction for pregabalin treatment of Class III prostatitis and CP/CPPS.

Selection criteria: Randomized controlled trials (RCTs) comparing pregabalin to placebo or other types of analgesics for the management of patients with CP/CPPS were included. Patients with known causes of pain/discomfort were excluded.

Data collection and analysis: Only one RCT was included. The trial compared pregabalin to placebo for patients who had CP/CPPS.

Main results: For men who responded clinically (≥ 6-point improvement), there was no difference between the pregabalin (103/218; 47.2%) and placebo (38/106; 35.8%) arms (risk ratio (RR) 1.32; 95% CI 0.99 to 1.76). There was less pain with a higher point improvement in the pregabalin group compared to the placebo group (4.2 points versus 1.7 points, respectively; mean difference (MD) -2.3 points; 95% CI -4.0 to -0.7 points).Though 59% (191/324) of the patients developed side effects, no serious effects were experienced. There were significantly more neurologic side effects in the pregabalin group compared to the placebo group (38.5% (84/218) versus 22.6% (24/106), respectively; RR 1.7; 95% CI 1.15 to 2.51), and less pain in the pregabalin group than in the placebo group (17.4% (38/218) versus 33.3% (35/106), respectively; RR 0.53; 95% CI 0.36 to 0.78). However, no significant differences were seen between the pregabalin and placebo groups with regards to gastrointestinal disturbances (18.3% (40/218) versus 18.9% (20/106), respectively; RR 0.97; 95% CI 0.60 to 1.58), ocular/visual symptoms (6.9% (15/218) versus 2.8% (3/106), respectively; RR 2.43; 95% CI 0.72 to 8.22), and renal/genitourinary symptoms (5.5% (12/218) versus 1.9% (2/106), respectively; RR 3.03; 95% CI 0.67 to 13.79).

Authors' conclusions: There is evidence from one RCT that pregabalin does not improve CP/CPPS symptoms and causes adverse effects in a large percentage of men. However, research is required to assess further whether pregabalin has a role in patients with CP/CPPS for symptom control.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Flow chart of article selection process.
2
2
'Risk of bias' graph: review authors' judgments about each 'Risk of bias' item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgments about each 'Risk of bias' item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009063

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Pontari 2010 {published data only}
    1. Pontari M, Krieger J, Litwin M, White P, Anderson R, McNaughton‐Collins M, et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Archives of Internal Medicine 2010;170(17):1586‐93. - PMC - PubMed

References to studies excluded from this review

Johansen 2002 {published data only}
    1. Johansen T, Weidner W. Understanding chronic pelvic pain syndrome. Current Opinion in Urology 2002;12:63‐7. - PubMed
Pontari 2007 {published data only}
    1. Pontari M, Joyce G, Wise M, McNaughton‐Collins M, and the Urologic Diseases in America Project. Prostatitis. The Journal of Urology 2006;177:2050‐7. - PubMed
Sikiru 2008 {published data only}
    1. Sikiru L, Shmaila H, Muhammed S. Transcutaneous electrical nerve stimulation (TENS) in the symptomatic management of chronic prostatitis/chronic pelvic pain syndrome: a placebo‐control randomized trial. International Brazilian Journal of Urology 2008;34:708‐14. - PubMed
Strauss 2010 {published data only}
    1. Strauss A, Dimitrakov J. New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nature Review Urology 2010;7:127‐35. - PMC - PubMed
Watanabe 2011 {published data only}
    1. Watanabe T, Inoue M, Sasaki K, Araki M, Uehara S, Monden K, et al. Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU International 2011;108(2):248‐51. - PubMed

Additional references

Arnold 2010
    1. Arnold L, Mease P, Silverman S. Pregabalin: an alpha2‐delta ligand for the management of fibromyalgia. American Journal of Management and Care 2010;16:S138‐43. - PubMed
Bartoletti 2007
    1. Bartoletti R, Mondaini N, Pavone C, Dinelli N, Prezioso D. Introduction to chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Archivio Italiano di Urologia e Andrologia 2007;79(2):55‐7. - PubMed
Cappuzzo 2009
    1. Cappuzzo K. Treatment of postherpetic neuralgia: focus on pregabalin. Clinical Interventions in Aging 2009;4:17‐23. - PMC - PubMed
Collins 1998
    1. Collins M, Stafford R, O'Leary M, Barry M. How common is prostatitis? A national survey of physician visits. The Journal of Urology 1998;159:1224‐8. - PubMed
CPCRN 2004
    1. The Chronic Prostatitis Collaborative Research Network. The economic impact of chronic prostatitis. Archives of Internal Medicine 2004;164:1231‐6. - PubMed
Dworkin 2005
    1. Dworkin R, Kirkpatrick P. Pregabalin. Nature Review Drug Discovery 2005;4:455‐6. - PubMed
Dworkin 2010
    1. Dworkin R, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinical Proceedings 2010;85(3):S3‐14. - PMC - PubMed
Gottsch 2010
    1. Gottsch HP, Yang CC, Berger RE. A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology 2010; Vol. 45, issue 1:72‐6. [PUBMED: 21062115] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jain 2005
    1. Jain KK. Clinical summary: pregabalin, 2011. www.medlink.com/medlinkcontent.asp (accessed 15 June 2012).
Krieger 1999
    1. Krieger J, Nyber L, Nickel JC. NIH consensus definition and classification of prostatitis. Journal of the American Medical Association 1999;282(3):236‐7. - PubMed
Litwin 1999
    1. Litwin M, McNaughton‐Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. The Journal of Urology 1999;162:369‐75. - PubMed
Magri 2010
    1. Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG, et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. The Journal of Urology 2010;184:2339‐45. - PubMed
McNaughton Collins 2008
    1. McNaughton Collins M, Wilt T. Allopurinol for chronic prostatitis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD001041] - DOI - PMC - PubMed
Miller 2002
    1. Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P, et al. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Urology 2002;59(4):603‐8. - PubMed
Nickel 2001
    1. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis‐like symptoms in a population based study using the National Institutes of Health Chronic Prostatitis Symptom Index. Journal of Urology 2001;165:842‐5. - PubMed
Online Symptom Index
    1. Chronic Prostatitis Collaborative Research Network. NIH Chronic Prostatitis Symptom Index. www.prostatitis.org/symptomindex.html (accessed 15 June 2012).
Pontari 2005
    1. Pontari M, McNaughton‐Collins M, O'Leary MP, Calhoun EA, Jang T, Kusek JW, et al. A case‐control study of risk factors in men with chronic pelvic pain syndrome. BJU International 2005;96(4):559‐65. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Reynard 2006
    1. Reynard J, Brewster S, Biers S. Oxford Handbook of Urology. 1st Edition. New York: Oxford University Press, 2006.
Roberts 1998
    1. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician‐assigned diagnosis of prostatitis: the Olmsted County study of urinary symptoms and health status among men. Urology 1998;51(4):578‐84. - PubMed
Weiss 2001
    1. Weiss R, George N, O'Reilly P. Comprehensive Urology. Vol. 1, London: Mosby, 2001. [ISBN: 0723429499]
Yang 2003
    1. Yang CC, Lee JC, Kromm BG, Ciol MA, Berger RE. Pain sensitization in male chronic pelvic pain syndrome: why are symptoms so difficult to treat?. Journal of Urology 2003;170(3):823‐7. - PubMed
Yilmaz 2007
    1. Yilmaz U, Liu YW, Berger RE, Yang CC. Autonomic nervous system changes in men with chronic pelvic pain syndrome. Journal of Urology 2007;177:2170‐4. - PubMed

Publication types

LinkOut - more resources